Format

Send to

Choose Destination
Oncotarget. 2010 Nov;1(7):530-43.

Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs.

Author information

1
Centre for Cancer Research, Monash Institute of Medical Research, Southern Health, Melbourne, Victoria, Australia.

Abstract

It is well established that the PI3K pathway plays a central role in various cellular processes that can contribute to the malignant phenotype. Accordingly, pharmacological inhibition of key nodes in this signaling cascade has been a focus in developmental therapeutics. To date, agents targeting upstream receptor tyrosine kinases are best studied and have achieved greatest clinical success. Further downstream, despite efficacy in certain tumor types, the rapalogs have been somewhat disappointing in the clinic. Novel inhibitors of PI3K, Akt, and mTORC1 and 2 are now passing through early phase clinical trials. It is hoped that these agents will circumvent some of the shortcomings of the rapalogs and lead to meaningful benefits for cancer patients.

PMID:
21317449
PMCID:
PMC3248125
DOI:
10.18632/oncotarget.101012
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center